| 1 |
Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, Nanthapisal S, Tanprasertkul C, Sritipsukho N, Mingmalairak C, Apisarnthanarak A, Tantiyavarong P. Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? Emerg Microbes Infect 2023;12:2174779. [PMID: 36715323 DOI: 10.1080/22221751.2023.2174779] [Reference Citation Analysis]
|
| 2 |
Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, Klein NP, DeSilva MB, Ong TC, Gaglani M, Hartmann E, Dickerson M, Stenehjem E, Kharbanda AB, Han J, Spark TL, Irving SA, Dixon BE, Zerbo O, McEvoy CE, Rao S, Raiyani C, Sloan-Aagard C, Patel P, Dascomb K, Uhlemann AC, Dunne MM, Fadel WF, Lewis N, Barron MA, Murthy K, Nanez J, Griggs EP, Grisel N, Annavajhala MK, Akinseye A, Valvi NR, Goddard K, Mamawala M, Arndorfer J, Yang DH, Embí PJ, Fireman B, Ball SW, Tenforde MW. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open 2023;6:e232598. [PMID: 36920396 DOI: 10.1001/jamanetworkopen.2023.2598] [Reference Citation Analysis]
|
| 3 |
Oyebanji OA, Mylonakis E, Canaday DH. Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infect Dis Clin North Am 2023;37:27-45. [PMID: 36805013 DOI: 10.1016/j.idc.2022.11.002] [Reference Citation Analysis]
|
| 4 |
Jeong YJ, Wi YM, Park H, Lee JE, Kim SH, Lee KS. Current and Emerging Knowledge in COVID-19. Radiology 2023;306:e222462. [PMID: 36625747 DOI: 10.1148/radiol.222462] [Reference Citation Analysis]
|
| 5 |
Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Petrone D, Bressi M, Del Manso M, Siddu A, Proietti V, Battilomo S, Menniti-Ippolito F, Popoli P, Bella A, Riccardo F, Palamara AT, Rezza G, Brusaferro S, Pezzotti P; Italian Integrated Surveillance of COVID-19 study group, of the Italian COVID-19 Vaccines Registry group. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study. Vaccine 2023;41:76-84. [PMID: 36400660 DOI: 10.1016/j.vaccine.2022.11.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. Front Immunol 2023;14:1104124. [PMID: 36776853 DOI: 10.3389/fimmu.2023.1104124] [Reference Citation Analysis]
|
| 7 |
Ellis R, Weiss A. Human Vaccines & Immunotherapeutics: News July 2022. Hum Vaccin Immunother 2022;18:2110829. [PMID: 35984390 DOI: 10.1080/21645515.2022.2110829] [Reference Citation Analysis]
|
| 8 |
Chia TRT, Young BE, Chia PY. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann Acad Med Singap 2022;51:712-729. [DOI: 10.47102/annals-acadmedsg.2022294] [Reference Citation Analysis]
|
| 9 |
Mollura M, Sarti R, Levi R, Pozzi C, Azzolini E, Politi LS, Mantovani A, Barbieri R, Rescigno M. Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers. Viruses 2022;14. [PMID: 36560609 DOI: 10.3390/v14122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Kim J, Seo H, Kim HW, Kim D, Kwon HJ, Kim YK. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. Viruses 2022;14. [PMID: 36366556 DOI: 10.3390/v14112458] [Reference Citation Analysis]
|
| 11 |
Link-gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, Klein NP, Desilva MB, Ong TC, Gaglani M, Hartmann E, Dickerson M, Stenehjem E, Kharbanda AB, Han J, Spark TL, Irving SA, Dixon BE, Zerbo O, Mcevoy CE, Rao S, Raiyani C, Sloan-aagard C, Patel P, Dascomb K, Uhlemann A, Dunne MM, Fadel WF, Lewis N, Barron MA, Murthy K, Nanez J, Griggs EP, Grisel N, Annavajhala MK, Akinseye A, Valvi NR, Goddard K, Mamawala M, Arndorfer J, Yang D, Embí PJ, Fireman B, Ball SW, Tenforde MW. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods.. [DOI: 10.1101/2022.10.04.22280459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Mcconeghy KW, White EM, Blackman C, Santostefano CM, Lee Y, Rudolph JL, Canaday D, Zullo AR, Jernigan JA, Pilishvili T, Mor V, Gravenstein S. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents — 19 States, March 29–July 25, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1235-1238. [DOI: 10.15585/mmwr.mm7139a2] [Reference Citation Analysis]
|
| 13 |
Gabrielli M. COVID-19 in Older Adults at the Time of the Omicron Variant. JCM 2022;11:5273. [DOI: 10.3390/jcm11185273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 14 |
Brynjolfsson SF, Sigurgrimsdottir H, Gudlaugsson O, Kristjansson M, Kristinsson KG, Ludviksson BR. Determining SARS-CoV-2 non-infectivity state-A brief overview. Front Public Health 2022;10:934242. [PMID: 36033758 DOI: 10.3389/fpubh.2022.934242] [Reference Citation Analysis]
|
| 15 |
Toniutto P, Cussigh A, Cmet S, Falleti E. Vaccination against SARS-CoV-2 in liver transplant recipients: The game is still long and the outcome is uncertain. Liver Int 2022;42:2341. [PMID: 35906808 DOI: 10.1111/liv.15369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
